ArticleSAGE open medicine2016
Pharmacogenomically actionable medications in a safety net health care system.
Article in SAGE open medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.Genetics in medicine : official journal of the American College of Medical Genetics · 2020Pooled it
- Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.Pharmacogenomics · 2019Trial
- Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Journal of the American Geriatrics Society · 2025Article
- Real-World Utilization of Medications With Pharmacogenetic Recommendations in Older Adults: A Scoping Review.Clinical and translational science · 2025Article
- Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.Human genetics · 2022Review
- Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.JAMA network open · 2021Article
- Use of Pharmacogenetic Drugs by the Dutch Population.Frontiers in genetics · 2019Article
- Medication Exposure Patterns in Primary Care Patients Prescribed Pharmacogenetically Actionable Opioids.Qualitative report (Online) · 2018Article
- Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.Clinical pharmacology and therapeutics · 2018Review
- Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.Pharmaceutical research · 2017Review
- Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network.BMC medical genomics · 2017Article
- Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
- Patient experiences with pharmacogenetic testing in a primary care setting.Pharmacogenomics · 2016Article
- Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study.Pharmacogenomics and personalized medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePrior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites.
methodsUsing 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited.
resultsResults showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system.
conclusionFindings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.